1. The ADAM17 inhibitor ZLDI-8 sensitized hepatocellular carcinoma cells to sorafenib through Notch1-integrin β-talk
- Author
-
Chang Xu, Xudong Gao, Tianshu Ren, Hefeng Geng, Kaisi Yang, Yaoguang Huang, Weige Zhang, Shanbo Hou, Aigang Song, Yingshi Zhang, and Qingchun Zhao
- Subjects
Notch1 ,Integrinβ ,ILK ,Sorafenib ,Crosstalk ,Therapeutics. Pharmacology ,RM1-950 - Abstract
ZLDI-8 is an A disintegrin and metalloproteinase domain 17 (ADAM17) inhibitor that suppresses the shedding of Notch1 to the Notch1 intracellular domain (NICD). In previous studies, we found that ZLDI-8 was able to sensitize HCC to sorafenib, but the mechanism of action remains unclear. The sensitizing effects of ZLDI-8 were tested both in vitro and in vivo. EMT-related factors, sorafenib sensitivity-related proteins and ECM-related gene expression were assessed using immunohistochemistry, RTPCR and Western blotting. Knockdown assays were conducted to determine the relationship between the Notch and Integrin pathways. CoIP assays, nuclear and cytoplasmic fractionation and immunofluorescence colocalization were applied to explore the interaction between the Notch and Integrin pathways. Appropriate statistical analysis methods were used to assess the significance of the experimental results and to ensure the scientific validity and reliability of the experimental design. We found that ECM- and EMT-related proteins were downregulated after ZLDI-8 treatment (P
- Published
- 2024
- Full Text
- View/download PDF